Protox to present interim prostate cancer data at AUA conference

    VANCOUVER, Sept. 6 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today
announced that interim data from the recently completed Phase 1 clinical study
testing PRX302 in patients with locally recurrent prostate cancer following
radiation failure will be presented at the American Urological Association
("AUA") South Central Section Annual Meeting. The conference will take place
at the Broadmoor Hotel in Colarado Springs, Colarado.
    Scott Coffield, M.D., Principal Investigator from the lead site at Scott
and White Memorial Hospital, will present the data on Friday, September 7,
2007. The presentation, entitled "Interim Results of a Phase 1 Clinical Study
for the Transperineal Intraprostatic Administration of PRX302 (PSA-PAH1) in
Patients with Locally Recurrent Prostate Cancer" indicates that PRX302 is safe
and well tolerated in patients and that it shows encouraging signs of
therapeutic activity.
    PRX302 is rationally designed to kill prostate cancer and hyperplastic
cells that over-produce the enzyme prostate specific antigen (PSA). Patient
enrollment has been completed for this Phase 1 study and top-line results were
released in July indicating that PRX302 is safe and well tolerated and that a
maximum tolerated dose was not reached in the study while encouraging signs of
therapeutic activity were observed. Plans are currently underway to commence a
Phase 2 study before the end of the year.

    About Protox

    Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for the treatment of cancer and other proliferative
diseases. The company is actively developing two distinct but complementary
platforms, INxin(TM) and PORxin(TM), and currently has four clinical programs
in development. A Phase 2a clinical trial into the use of PRX321 (INxin) for
the treatment of primary brain cancer has been completed and the drug has
received Fast Track Designation and Orphan Drug Status from the US FDA. In
addition, a Phase 1 trial has been completed for PRX321 to treat patients with
renal cell carcinoma and non-small cell lung cancer. Patient enrollment has
been completed for a Phase 1 clinical trial into the use of PRX302 (PORxin)
for the treatment of localized prostate cancer. A Phase 1 clinical study of
PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate)
is ongoing.


    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information:

For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199,; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,

Organization Profile

Sophiris Bio, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890